| 2024-10-03 |
详情>>
股本变动：
变动后总股本135.00万股
|
| 2024-08-26 |
详情>>
内部人交易：
Radoff Bradley Louis共交易3笔
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益4.35美元,归母净利润557.76万美元,同比去年增长972.42%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-3.71美元,归母净利润-474.67万美元,同比去年增长-990.42%
|
| 2024-04-08 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To approve the sale of all of the outstanding equity interests (the “Transaction”) of Activ Nutritional, LLC (“Activ”), a Delaware limited liability company which owns the Viactiv brand and business and is the wholly-owned subsidiary of Viactiv Nutritionals, Inc (“Viactiv”), a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to an Equity Purchase Agreement with Doctor’s Best Inc., a Delaware corporation (“Doctor’s Best”), dated January 30, 2024 (the “Purchase Agreement”);
2.To approve the voluntary dissolution and liquidation of the Company (the “Dissolution”) pursuant to a Plan of Dissolution (the “Plan of Dissolution”), which, if approved, will authorize the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution, but subject to the Company’s ability to abandon or delay the Plan of Dissolution in accordance with the terms thereof;
3.To grant discretionary authority to our Board to adjourn the Special Meeting to a later date, if necessary or appropriate, to allow for the solicitation of additional proxies only in the event that there are insufficient shares present virtually or represented by proxy voting in favor of the Transaction or the Plan of Dissolution;
4.To transact such other business as may properly come before the Special Meeting.
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益0.12美元,归母净利润15.80万美元,同比去年增长101.00%
|
| 2024-01-31 |
复牌提示：
2024-01-31 09:38:34 停牌，复牌日期 2024-01-31 09:43:34
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.21美元,归母净利润-26.67万美元,同比去年增长95.57%
|
| 2023-10-03 |
股东大会：
将于2023-11-21召开股东大会
会议内容 ▼▲
- 1.To elect four members to our board of directors;
2.To ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.5美元,归母净利润-63.93万美元,同比去年增长85.20%
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益0.42美元,归母净利润53.31万美元,同比去年增长120.36%
|
| 2023-04-17 |
详情>>
业绩披露：
2022年年报每股收益-14.15美元,归母净利润-1586.38万美元,同比去年增长35.89%
|
| 2023-01-09 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2022-12-12 |
股东大会：
将于2023-01-05召开股东大会
会议内容 ▼▲
- 1.To grant discretionary authority to our board of directors to (i) amend our Certificate of Incorporation, as amended, to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split”, at a specific ratio for the combination, up to a maximum of a 1-for-100 split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by our stockholders;
2.To transact such other matters as may properly come before the Special Meeting and any adjournment or postponement thereof.
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.11美元,归母净利润-601.66万美元,同比去年增长41.16%
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-0.09美元,归母净利润-432.05万美元,同比去年增长40.08%
|
| 2022-05-12 |
详情>>
业绩披露：
2022年一季报每股收益-0.07美元,归母净利润-261.85万美元,同比去年增长1.91%
|
| 2022-04-21 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect five members to our board of directors;
2.To ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To consider and act upon a proposal to approve an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of common stock issuable thereunder to 10,000,000 shares from 1,666,666 shares;
4.To grant discretionary authority to our board of directors to (i) amend our Certificate of Incorporation, as amended, to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of no split to a maximum of a 1-for-30 split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by our stockholders;
5.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-25 |
股东大会：
将于2021-10-22召开股东大会
会议内容 ▼▲
- 1.To elect five members to our board of directors;
2.To ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, our 2020 named executive officer compensation;
4.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-03-01 |
详情>>
拆分方案：
每6.0000合并分成1.0000股
|
| 2020-09-08 |
股东大会：
将于2020-10-29召开股东大会
会议内容 ▼▲
- 1.To elect five (5) members to our board of directors;
2.To ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares issuable thereunder to 10,000,000 shares from 3,000,000 shares;
4.To extend the previously-granted discretionary authority of our board of directors to amend our certificate of incorporation, without in any way affecting the prior authorization, to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of no split to a maximum of a one-for-thirty (1-for-30) split, with the exact ratio to be determined by our board of directors in its sole discretion, from the current authorization date through December 5, 2020, to within one year of the date this new proposal is approved by stockholders, or October 29, 2021 (the “Reverse Split Extension”).
5.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2019-11-06 |
股东大会：
将于2019-12-05召开股东大会
会议内容 ▼▲
- 1.To elect five (5) members to our board of directors;
2.To ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To amend our certificate of incorporation to increase the number of shares of authorized common stock from 90,000,000 to 250,000,000;
4.To grant discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of no split to a maximum of a one-for-thirty (1-for-30) split, with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders;
5.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-10-22 |
股东大会：
将于2018-11-20召开股东大会
会议内容 ▼▲
- 1.Elect each of Michael Favish, Robert Weingarten, Mark Goldstone and David W. Evans as members of our Board of Directors;
2.Ratify the appointment of Weinberg & Company, P.A. as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.Approve the Guardion Health Sciences, Inc. 2018 Equity Incentive Plan;
4.Grant discretionary authority to our Board of Directors to (i) amend our Certificate of Incorporation to combine outstanding shares of our common stock into a lesser number of outstanding shares, or a “reverse stock split”, at a specific ratio within a range of one-for-two and three-for-four, with the exact ratio to be determined by our Board of Directors in its sole discretion and (ii) effect a reverse stock split, if at all, within one year of the date the proposal is approved by stockholders (the “Reverse Stock Split Proposal”);
5.Hold an advisory vote on our 2017 named executive officer compensation;
6.Hold an advisory vote on the frequency of the advisory vote on executive compensation;
7.Authorize the adjournment or postponement of the Annual Meeting if necessary or appropriate, including to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals.
|